METASTATIC NON SMALL CELL LUNG CANCER
Clinical trials for METASTATIC NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for METASTATIC NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising new combo aims to improve lung cancer treatment
Disease control OngoingThis study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab) against standard treatment for advanced non-small cell lung cancer. It includes about 1,170 adults whose tumors have low PD-L1 levels and no specific gene changes. The goal is to see if the new co…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug duo aims to slow advanced lung cancer
Disease control OngoingThis phase 3 trial tests whether adding the drug Dato-DXd to standard immunotherapy (pembrolizumab) helps people with advanced or metastatic non-small cell lung cancer live longer without their cancer growing. About 740 adults with a high level of a protein called PD-L1 will be r…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug combo aims to fight lung cancer without chemo
Disease control OngoingThis study tests whether two immunotherapy drugs, balstilimab and botensilimab, are safe and effective as a first treatment for people with metastatic non-small cell lung cancer. The trial includes 45 participants who have not had prior treatment for advanced disease. Researchers…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Immune Oncology Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for lung cancer: immunotherapy cocktail under study
Disease control OngoingThis phase 2 trial is testing whether combining the immunotherapy drug tislelizumab with other experimental drugs, with or without chemotherapy, can shrink tumors and control advanced non-small cell lung cancer. About 400 people who have not had prior treatment for metastatic dis…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for lung cancer: experimental drug volrustomig takes on standard therapy
Disease control OngoingThis Phase 3 trial is testing whether a new drug called volrustomig, combined with chemotherapy, works better than the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has spread. The study includes about 1,200 partici…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for Hard-to-Treat lung cancer: targeted drug shows promise in early trial
Disease control OngoingThis early-stage study tests a new drug called furmonertinib in about 160 people with advanced or spreading non-small cell lung cancer that has certain gene changes (EGFR or HER2 mutations). The goal is to see if the drug is safe and can shrink tumors. Participants must have alre…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New immunotherapy combo shows promise for stage IV lung cancer
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
CRISPR Gene-Edited immune cells aim to fight lung cancer – but trial never started
Disease control TerminatedThis early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the tria…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Intima Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo therapy offers hope for lung cancer patients who stopped responding to initial treatment
Disease control OngoingThis study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose disease worsened after initial chemo-immunotherapy. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo therapy aims to stall lung cancer progression
Disease control OngoingThis study tests whether adding the experimental drug APL-101 to standard osimertinib can better control EGFR-mutated metastatic non-small cell lung cancer. About 27 adults who have already started osimertinib without their cancer getting worse will receive the combination until …
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Blood test may guide lung cancer therapy, avoiding unnecessary chemo
Disease control OngoingThis study is testing whether a blood test that looks for cancer DNA can tell if immunotherapy alone is working for people with advanced non-small cell lung cancer. If the test shows the cancer is not responding, patients would switch to immunotherapy plus chemotherapy. The goal …
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Julia K. Rotow, MD • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail shows promise in slowing EGFR lung cancer
Disease control OngoingThis Phase 3 trial tests whether adding ramucirumab (a drug that blocks blood vessel growth) to the standard targeted therapy erlotinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) live longer without their cancer getting worse. About 545 peop…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Zap and delay: radiation may buy time for cancer patients
Disease control OngoingThis study looks at whether giving precise, high-dose radiation to a small number of growing cancer spots can help people with metastatic non-small cell lung cancer stay stable longer. About 90 adults whose cancer has started to grow in just a few places while on standard treatme…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: NA • Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Could two extra drugs revive immunotherapy for tough lung cancers?
Disease control OngoingThis early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Thomas Marron • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Targeted radiation may extend life for patients with limited bone metastases
Disease control OngoingThis study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: NA • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Lung cancer patients may soon get immunotherapy as a quick shot
Disease control OngoingThis study tests whether a subcutaneous (under-the-skin) injection of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer. About 39 Japanese adults will receive either the shot or the IV, both combined with chemotherapy. T…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Lung cancer immunotherapy could soon be a simple shot instead of an IV drip
Disease control OngoingThis phase 3 trial compares a new subcutaneous (under-the-skin) injection of the immunotherapy drug pembrolizumab, combined with chemotherapy, against the standard intravenous (IV) infusion for people with metastatic non-small cell lung cancer who have not had prior treatment. Th…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 26, 2026 16:50 UTC
-
Blood test could replace painful biopsies for cancer patients
Knowledge-focused OngoingThis study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…
Matched conditions: METASTATIC NON SMALL CELL LUNG CANCER
Phase: NA • Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC